Urology Times

The ModernMedicine Network is a comprehensive platform that unites news, resources, tools, and educational programs from reliable and respected sources. It is curated by a team of experts, including advisors, consultants, influential voices, and content partners. ModernMedicine serves as a central news source for professionals in the healthcare industry.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#351494

United States

#124390

Health/Medicine

#1040

Traffic sources

Monthly visitors

Articles

We got a little MIST-y at this year’s AUA Annual Meeting

4 days ago | urologytimes.com | Garrett D. Pohlman

Once upon a time, patients seeking interventional treatment for benign prostatic hyperplasia (BPH) were faced with a lifetime of taking daily medication, maybe undergoing a transurethral resection of the prostate, or perhaps a simple open prostatectomy. But today, if you’re one of the millions of men with BPH, there have never been more options for you to get relief from your symptoms.
Durvalumab plus BCG significantly improves DFS in NMIBC

6 days ago | urologytimes.com | Benjamin P. Saylor |Hannah Clarke

Treatment for 1 year with durvalumab (Imfinzi) plus standard-of-care BCG induction and maintenance therapy was associated with a statistically significant and clinically meaningful improvement in disease-free survival (DFS) high-risk non–muscle invasive bladder cancer (NMIBC) vs BCG induction and maintenance alone, AstraZeneca announced.1 According to the company, although the phase 3 POTOMAC trial (NCT03528694) was statistically powered to formally evaluate overall survival, “a descriptive...
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world

1 week ago | urologytimes.com | Stephen J. Freedland |Benjamin P. Saylor

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments.1 Investigators found that benefits of treatments that are observed in trials also appear in the real world. In a recent interview with Urology Times®, study author Stephen J. Freedland, MD, discussed the findings, one of which was that real-world overall survival gains appeared to increase with the duration a new therapy was on the market.
Assessing Risk in NMIBC: A Foundation for Therapy

1 week ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

Author(s):,Panelists discuss how precise risk stratification in non–muscle-invasive bladder cancer enables physicians to tailor treatment and surveillance strategies based on individual patient risk profiles. Physician Summary:Effective management of non–muscle-invasive bladder cancer (NMIBC) hinges on precise risk stratification. Accurate assessment of patient risk is foundational, guiding the choice of treatment intensity, surveillance frequency, and decisions around intravesical therapy.
From Papillary to CIS: Tailoring NMIBC Treatment

1 week ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

Author(s):,Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer. Physician Summary:Specific tumor features—such as papillary architecture and the presence of carcinoma in situ (CIS)—play a critical role in shaping treatment decisions for NMIBC.
Expert discusses the NMIBC trials landscape

1 week ago | urologytimes.com | Joshua J. Meeks |Benjamin P. Saylor

In a recent interview with Urology Times®, Joshua J. Meeks, MD, PhD, shared his thoughts on some of the notable ongoing trials in the non–muscle invasive bladder cancer (NMIBC) space and what urologists should be on the look-out for. “For a NMIBC, all you have to do is look forward to the metastatic setting.
AUA Advocacy Summit: Medicare payment reform among top priorities

1 week ago | urologytimes.com | Jennifer Miles-Thomas |Benjamin P. Saylor

The American Urological Association (AUA) conducted its Annual Advocacy Summit March 3-5, 2025. The organization came to the gathering with 4 key priorities:1. Medicare payment reform. The current Medicare payment system has been identified as a significant concern. Reforming this system is a top priority for the AUA to ensure fair and sustainable reimbursement for urological care. 2.
AUA 2025 recap: Urologic oncology trials in progress

1 week ago | urologytimes.com | Hannah Clarke

The 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada featured several sessions on ongoing clinical trials in urologic oncology. These spanned several up-and-coming agents in the non–muscle invasive bladder cancer (NMIBC) space, as well as potential practice-informing studies in both prostate and kidney cancer. Take a look through some of the notable studies that were spotlighted during this year’s meeting.
FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

1 week ago | urologytimes.com | Hannah Clarke

The FDA has issued a refusal to file (RTF) letter to ImmunityBio in regard to their supplemental biologics license application (sBLA) for use of nogapendekin alfa inbakicept-pmln (NAI; Anktiva) in combination with BCG for BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) in the papillary indication, the company announced in a news release.1 According to ImmunityBio, this letter comes after receiving unanimous guidance to submit the sBLA from leadership at the agency during an...
Health policy expert highlights the importance of state-level urology advocacy

1 week ago | urologytimes.com | Benjamin P. Saylor

Hans Arora, MD, PhD, has attended every iteration of the American Urological Association (AUA) Annual Urology Advocacy Summit to date, and according to him, “Every year, it changes a little bit.” Arora, who is an assistant professor of urology and director of robotic surgery in pediatric urology at the University of North Carolina in Chapel Hill, explained that “one of the really interesting things about the AUA Advocacy Summit, which can be different from other society summits, is that they...